Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Study to Evaluate the Ability of Speech- and Language-based Digital Biomarkers to Detect and Characterise Prodromal and Preclinical Alzheimer's Disease in a Clinical Setting - FUTURE Extension Study.

NCT04846426 is registered in ClinicalTrials.gov with Novoic Limited as lead sponsor.

NCT NCT04846426
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04846426 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Study to Evaluate the Ability of Speech- and Language-based Digital Biomarkers to Detect and Characterise Prodromal and Preclinical Alzheimer's Disease in a Clinical Setting - FUTURE Extension Study.
Lead sponsor
Novoic Limited
Phase
Observational
Overall status
Terminated
Start date
November 19, 2020
Completion date
June 7, 2024
Enrollment
67 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

alzheimer disease, alzheimer's disease (incl subtypes), mild cognitive impairment, preclinical alzheimer's disease, prodromal alzheimer's disease